OA11513A - Composés morpholiniques antagonistes du récepteur de la NK-1. - Google Patents

Composés morpholiniques antagonistes du récepteur de la NK-1. Download PDF

Info

Publication number
OA11513A
OA11513A OA1200000324A OA1200000324A OA11513A OA 11513 A OA11513 A OA 11513A OA 1200000324 A OA1200000324 A OA 1200000324A OA 1200000324 A OA1200000324 A OA 1200000324A OA 11513 A OA11513 A OA 11513A
Authority
OA
OAPI
Prior art keywords
compound
formula
receptor
morpholin
acid
Prior art date
Application number
OA1200000324A
Other languages
English (en)
French (fr)
Inventor
Theresa Maria Ballard
Guy Andrew Higgins
Torsten Hoffmann
Sonia Maria Poli
Andrew Sleight
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of OA11513A publication Critical patent/OA11513A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
OA1200000324A 1999-11-29 2000-11-29 Composés morpholiniques antagonistes du récepteur de la NK-1. OA11513A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
OA11513A true OA11513A (fr) 2004-02-03

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000324A OA11513A (fr) 1999-11-29 2000-11-29 Composés morpholiniques antagonistes du récepteur de la NK-1.

Country Status (50)

Country Link
EP (1) EP1103545B1 (is)
JP (1) JP3480835B2 (is)
KR (1) KR100390117B1 (is)
CN (1) CN1152016C (is)
AR (1) AR033659A1 (is)
AT (1) ATE253561T1 (is)
AU (1) AU775292B2 (is)
BG (1) BG64622B1 (is)
BR (1) BRPI0005616B8 (is)
CA (1) CA2326529C (is)
CO (1) CO5251405A1 (is)
CZ (1) CZ299286B6 (is)
DE (2) DE60006340T2 (is)
DK (1) DK1103545T3 (is)
DO (1) DOP2000000106A (is)
EA (1) EA004404B1 (is)
ES (2) ES2208205T3 (is)
FR (1) FR2801590A1 (is)
GB (1) GB2356863A (is)
GC (1) GC0000151A (is)
GE (1) GEP20022763B (is)
GT (1) GT200000197A (is)
HK (1) HK1036759A1 (is)
HR (1) HRP20000809A2 (is)
HU (1) HU224703B1 (is)
ID (1) ID28483A (is)
IL (1) IL139868A (is)
IS (1) IS2212B (is)
IT (1) IT1320120B1 (is)
JO (1) JO2298B1 (is)
MA (1) MA26754A1 (is)
MX (1) MXPA00011672A (is)
MY (1) MY127426A (is)
NO (1) NO317264B1 (is)
NZ (1) NZ508386A (is)
OA (1) OA11513A (is)
PA (1) PA8507201A1 (is)
PE (1) PE20010901A1 (is)
PL (1) PL195957B1 (is)
PT (1) PT1103545E (is)
SG (1) SG97171A1 (is)
SI (1) SI1103545T1 (is)
SK (1) SK285373B6 (is)
SV (1) SV2002000227A (is)
TN (1) TNSN00226A1 (is)
TR (1) TR200302077T4 (is)
UA (1) UA70326C2 (is)
UY (1) UY26458A1 (is)
YU (1) YU73400A (is)
ZA (1) ZA200006964B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496032T1 (de) * 1999-02-24 2011-02-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
TR200102490T2 (tr) * 1999-02-24 2001-12-21 F.Hoffmann-La Roche Ag Fenil ve piridinil türevleri
RS50932B (sr) * 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
IL162733A0 (en) * 2002-01-31 2005-11-20 Hoffmann La Roche Genetic polymorphisms in the preprotachykinin gene
NZ544244A (en) 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
JP4580426B2 (ja) 2004-07-06 2010-11-10 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
PL1863767T3 (pl) * 2005-03-23 2009-08-31 Helsinn Healthcare Sa Metabolity antagonistów NK-1 do leczenia wymiotów
DK1928427T3 (da) * 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CA2903022C (en) 2013-03-15 2021-11-09 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20160078997A (ko) 2013-11-08 2016-07-05 깃세이 야쿠힌 고교 가부시키가이샤 카복시메틸피페리딘 유도체
JP6809681B2 (ja) 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916346A3 (en) * 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
BR9408442A (pt) * 1993-12-29 1997-08-05 Merck Sharp & Dohme Composto composição farmacêutica processos para tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquiquininas e para a preparação do composto e de uso do composto
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DE69628484T2 (de) * 1995-03-24 2004-05-19 Takeda Chemical Industries, Ltd. Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
ATE496032T1 (de) * 1999-02-24 2011-02-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
RS50932B (sr) * 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
UA70326C2 (en) 2004-10-15
NO20006012L (no) 2001-05-30
CA2326529A1 (en) 2001-05-29
KR100390117B1 (ko) 2003-07-04
IT1320120B1 (it) 2003-11-18
IL139868A0 (en) 2002-02-10
PT1103545E (pt) 2004-03-31
DE60006340D1 (de) 2003-12-11
EA200001114A2 (ru) 2001-08-27
CO5251405A1 (es) 2003-02-28
CZ20004399A3 (cs) 2001-07-11
YU73400A (sh) 2003-02-28
JP2001151754A (ja) 2001-06-05
HK1036759A1 (en) 2002-01-18
ZA200006964B (en) 2001-06-05
PA8507201A1 (es) 2002-02-21
SK285373B6 (sk) 2006-12-07
HU224703B1 (en) 2006-01-30
PE20010901A1 (es) 2001-09-20
BG104992A (en) 2001-11-30
AU7178700A (en) 2001-05-31
BR0005616A (pt) 2001-07-17
AR033659A1 (es) 2004-01-07
IS2212B (is) 2007-02-15
SV2002000227A (es) 2002-02-05
CZ299286B6 (cs) 2008-06-04
UY26458A1 (es) 2001-05-31
NO20006012D0 (no) 2000-11-28
PL195957B1 (pl) 2007-11-30
KR20010051983A (ko) 2001-06-25
MY127426A (en) 2006-11-30
DE10058310A1 (de) 2001-05-31
FR2801590A1 (fr) 2001-06-01
TR200302077T4 (tr) 2004-01-21
ES2171134A1 (es) 2002-08-16
PL344147A1 (en) 2001-06-04
JP3480835B2 (ja) 2003-12-22
AU775292B2 (en) 2004-07-29
MA26754A1 (fr) 2004-12-20
HU0004725D0 (is) 2001-02-28
HRP20000809A2 (en) 2001-12-31
ES2208205T3 (es) 2004-06-16
BG64622B1 (bg) 2005-09-30
ID28483A (id) 2001-05-31
EP1103545B1 (en) 2003-11-05
CN1152016C (zh) 2004-06-02
TNSN00226A1 (fr) 2002-05-30
JO2298B1 (en) 2005-09-12
BRPI0005616B8 (pt) 2021-07-06
EA200001114A3 (ru) 2001-12-24
IS5725A (is) 2001-05-29
IL139868A (en) 2009-09-01
SG97171A1 (en) 2003-07-18
NZ508386A (en) 2003-02-28
GB2356863A (en) 2001-06-06
HUP0004725A2 (hu) 2002-04-29
CN1297888A (zh) 2001-06-06
NO317264B1 (no) 2004-09-27
SK17932000A3 (sk) 2001-11-06
MXPA00011672A (es) 2002-08-20
BRPI0005616B1 (pt) 2017-12-12
CA2326529C (en) 2009-12-22
EA004404B1 (ru) 2004-04-29
GB0028566D0 (en) 2001-01-10
ITMI20002575A1 (it) 2002-05-29
SI1103545T1 (en) 2004-02-29
GT200000197A (es) 2002-05-22
EP1103545A1 (en) 2001-05-30
DK1103545T3 (da) 2004-03-15
ATE253561T1 (de) 2003-11-15
DOP2000000106A (es) 2002-07-30
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
GEP20022763B (en) 2002-08-26

Similar Documents

Publication Publication Date Title
OA11513A (fr) Composés morpholiniques antagonistes du récepteur de la NK-1.
DE69403823T2 (de) Substituierte Phenylsulfonamine als selektive B3-Agonisten zur Behandlung von Diabetes und Fettleibigkeit
JP4118673B2 (ja) ニューロキニン１受容体アンタゴニストとしての４−フェニル−ピリジン誘導体
OA11680A (fr) Nouveaux composés et médicaments les contenant.
JP4700908B2 (ja) ２−（３，５−ビス−トリフルオロメチル−フェニル）−Ｎ−〔６−（１，１−ジオキソ−１λ６−チオモルホリン−４−イル）−４−（２−メチル又は４−フルオロ−２−メチル置換）フェニル−ピリジン−３−イル〕−Ｎ−メチル−イソブチルアミド
JP4768010B2 (ja) 嘔吐のためのｎｋ−１アンタゴニストの代謝物
KR100437561B1 (ko) 신규헤테로고리화합물
EP1856052A2 (en) Nk1 antagonists